Taxim - O

Quick links to important sections

Taxim - O

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Taxim - O

Quick Facts

Property Description
Active ingredient Cefixime
Form Oral suspension, Tablet, Capsule
Pharmacological class Third-generation Cephalosporin Antibiotic
General purpose Elimination of systemic bacterial infections
Origin Semi-synthetic

What Type of Medicine is Taxim-O?

Taxim-O is a semi-synthetic, prescription-only medication whose active compound is Cefixime, utilized systemically to treat infections caused by susceptible bacteria. It is classified as a Third-generation Cephalosporin Antibiotic. This pharmacological class is clinically recognized for offering enhanced broad-spectrum coverage and greater stability against certain bacterial defense mechanisms when compared to earlier generations of cephalosporin drugs. This systemic agent is often utilized in scenarios requiring a reliable oral therapy to target a wide range of common pathogens.

Cefixime: The Active Ingredient and Available Forms

The medication is a single-active-ingredient product where Cefixime is the component responsible for the therapeutic effect. Taxim-O is manufactured primarily for oral administration, offering high flexibility by being available in the Tablet, the Capsule, and the Oral suspension forms. Pharmacological data indicate the high bioavailability of Cefixime after oral ingestion. The formulation specifically includes an oral suspension to effectively cater to pediatric patients and others who require liquid medications, ensuring its antimicrobial benefit is accessible across various patient groups.

General Role of Cefixime as an Antimicrobial Agent

The general purpose of Cefixime is to aid the body in eliminating systemic bacterial infections caused by susceptible organisms throughout the body. The drug functions through a powerful bactericidal action, meaning it actively kills susceptible pathogenic bacteria. This action is rooted in its ability to disrupt the final critical steps in the bacteria's cell wall synthesis. Its general role is to act as a definitive treatment in managing acute infectious conditions where the identified pathogen is susceptible to this broad-spectrum Third-generation Cephalosporin.

What side effects are possible with Taxim - O?

Possible Side Effects and Safety Information

The regulatory safety profile of Taxim-O (Cefixime) is primarily characterized by effects on the Gastrointestinal System, though it includes the potential for rare, serious systemic reactions, consistent with the cephalosporin class of antibiotics. Safety classifications are defined by official prescribing information, such as the FDA and EMA documents.

Documented Adverse Reactions and Organ System Effects

Frequency Classification Example Adverse Reaction System-Organ Class
Very Common (ge10%) Diarrhea Gastrointestinal Disorders
Common (1%–10%) Abdominal pain, Nausea, Headache Gastrointestinal, Nervous System
Uncommon (0.1%–1%) Rash, Pruritus Skin and Subcutaneous Tissue
Very Rare (<0.01%) Anaphylactic shock, SJS, TEN Immune System, Skin and Subcutaneous Tissue

Serious adverse reactions documented in regulatory sources include Anaphylactic Reactions and potentially life-threatening conditions like Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Additionally, Pseudomembranous Colitis (associated with Clostridioides difficile) and Acute Renal Failure are recognized serious risks.

Safety Considerations for Specific Populations

Official labeling notes that the safety and effectiveness have not been established in infants younger than six months of age. Patients with renal impairment (creatinine clearance less than 60 mL/min) require specific dose considerations due to slower clearance of the drug. The medicine is contraindicated in individuals with a known history of hypersensitivity to Cefixime or any other cephalosporin antibiotic. Furthermore, the oral suspension may contain phenylalanine, which is a safety constraint for individuals with Phenylketonuria (PKU).

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation notes that limited information is available regarding the acute toxicity of Cefixime in humans. Adverse reactions observed after exposure to doses up to 2 g in healthy subjects did not significantly differ from the profile seen at standard therapeutic doses, often including mild to moderate gastrointestinal effects.

Overdose manifestations of concern include the potential for Central Nervous System (CNS) effects, such as seizures and neurotoxicity, which are risks associated with the cephalosporin class. This risk is particularly noted in patients with renal impairment, as reduced drug clearance leads to higher systemic concentrations.

Feature Official Regulatory Statement
Antidote Status No specific antidote exists for Cefixime toxicity.
Dialysis Efficacy The drug is not removed in significant quantities from the circulation by either hemodialysis or peritoneal dialysis.
Management Measures Treatment is symptomatic and supportive, and should include close patient monitoring. Measures like gastric lavage may be indicated, and anticonvulsant therapy can be administered if seizures occur.

Urgent medical attention must be sought immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened, as stated in governmental guidance. In any case of suspected overdose, official patient information mandates contacting a Poison Control Helpline.

Therapeutic Uses of Taxim - O

Quick Facts: Therapeutic Areas

  • Supports resolution of uncomplicated urinary tract infections.
  • Assists in the management of bacterial throat and tonsil infections.
  • Contributes to the treatment of acute bronchitis and ear infections (otitis media).
  • May be prescribed for the management of certain bacterial sexually transmitted infections.

What Taxim - O Treats: Main Uses and Benefits

Taxim - O is a prescribed medication utilized for the management of certain bacterial infections. It is appropriate for use in adults and pediatric patients six months of age or older when the infection is confirmed or strongly suspected to be caused by susceptible bacteria. This medicine works to address a range of conditions across different body systems.

The medication is indicated for the treatment of uncomplicated urinary tract infections (UTIs), particularly those caused by susceptible strains of Escherichia coli and Proteus mirabilis. For respiratory conditions, it may be used to aid in the treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes, and is available for acute exacerbations of chronic bronchitis.

Infections affecting the ear, such as otitis media, respond to treatment with this agent. Additionally, Taxim - O is specified for the management of uncomplicated gonorrhea (cervical/urethral). Completing the full prescribed course is a standard requirement to achieve the intended therapeutic effect and help reduce the development of drug-resistant bacteria.

Eligibility and Restrictions for Use

The eligibility for using Taxim-O (Cefixime) is governed by official governmental regulatory documents, which strictly define the approved populations and those for whom use is contraindicated or restricted.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and Pediatric patients six months of age or older [FDA, EMA].
Populations for whom use is contraindicated Patients with known hypersensitivity to Cefixime or any other drug in the cephalosporin class of antibiotics [FDA, EMA].
Age-related restrictions Safety and effectiveness have not been established in infants younger than six months [FDA].
Condition-specific rules Patients with severe renal impairment must have their dosage adjusted due to slower drug clearance [EMA, FDA]. Caution is advised for those with a history of colitis or severe penicillin allergy.
Pregnancy/Lactation status Classified as Pregnancy Category B (use only if clearly needed) [FDA]. The drug may be excreted in breast milk, leading to the regulatory recommendation to consider temporarily discontinuing nursing [FDA].

Connection to the Overall Eligibility Profile

Regulatory labels define who can and cannot use this medicine through two main constraints: an absolute contraindication for known allergic history to cephalosporins, and conditional use based on age (minimum six months), existing renal function, and specific patient history (e.g., severe penicillin allergy). These statements outline the precise populations approved, restricted, or prohibited from using the medicine.

What should I know about interactions with other medicines?

Taxim - O Interactions with Other Medicines and Products

This section details officially documented interaction patterns for Taxim-O (Cefixime) based strictly on government regulatory information.

Pharmacodynamic and Coagulation Effects

Concomitant use of Cefixime with Warfarin and other anticoagulants has been associated with an increased prothrombin time, with reports of clinical bleeding. This pharmacodynamic effect is of particular relevance in patients with renal or hepatic impairment or those with a poor nutritional state.

Exposure-Altering Interactions

Interacting Substance Official Effect Mechanism Statement (Label-Based)
Probenecid Increases Cefixime Cmax and AUC Decreases Cefixime renal clearance
Carbamazepine Elevated Carbamazepine serum levels Interaction reported in postmarketing data
Nifedipine May increase Cefixime bioavailability Documented change in absorption
Salicylates (e.g., Aspirin) May decrease Cefixime Cmax and AUC Documented change in absorption

Constraints and Laboratory Tests

Co-administration with potentially nephrotoxic substances (e.g., aminoglycosides) may increase the risk of renal function impairment. Additionally, Cefixime may cause false-positive results for urine ketones (using the nitroprusside method) and urine glucose (non-glucose oxidase methods), as well as a false-positive direct Coombs test.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Synthesis

Taxim-O (Cefixime) operates by targeting and irreversibly binding to Penicillin-Binding Proteins (PBPs), which are bacterial enzymes required for the final cross-linking step of the peptidoglycan cell wall . This action falls under the mechanistic domain of structural synthesis interference. This binding prevents the bacterium from maintaining its structural integrity, a failure that leads to cell destruction.

The Bactericidal Cascade

The irreversible PBP inhibition triggers a rapid mechanistic cascade resulting in bacterial cell lysis and death. The compromised cell wall cannot withstand internal osmotic pressure, and this structural failure results in the bacterial cell rupturing. This pathway interference domain is associated with a bactericidal physiological effect, which results in the death of the susceptible bacterial population, in contrast to mechanisms that inhibit growth.

Limitations Due to Enzymatic Inactivation

The drug's mechanism is constrained by mechanistic limitations, primarily the bacterial production of beta-lactamase enzymes. These enzymes chemically inactivate Cefixime, preventing it from reaching the PBPs and completing its mechanism. This mechanistic domain defines the constraints on the mechanism's action against strains that utilize drug degradation mechanisms.

Dosage and Administration Information

Administration Guidelines

Taxim-O, containing the active ingredient Cefixime, is a medication approved for oral administration only. It is prescribed for use as a duration-limited course, with the total length of the course dependent on the specific infection being addressed.

Standard Dosing and Frequency

The standard adult dose for most approved systemic infections is 400 mg of Cefixime, typically administered once daily (QD). The total daily dose may also be administered in two divided doses taken every 12 hours. For the treatment of uncomplicated gonorrhea, the established regimen is a specific single oral dose of 400 mg. The drug may be taken without regard to food, allowing flexibility in its daily timing.

Population-Specific Use

For pediatric patients six months of age and older, the prescribed dose is weight-based, calculated at 8 mg/kg of body weight per day. This is administered via the oral suspension, which is required because of differences in absorption compared to other forms. A specific dose adjustment is required for adult patients diagnosed with impaired kidney function (creatinine clearance less than 60 mL/min) to manage systemic exposure.

Course Duration and Preparation

While general use ranges from 7 to 14 days, administration for infections caused by Streptococcus pyogenes requires treatment for a minimum of 10 days. If using the oral suspension, the powder must be reconstituted with water and shaken well before each use to ensure the correct dose is measured. The reconstituted suspension must be discarded after 14 days.

Recent Clinical Evidence

Taxim - O: Recent Clinical Evidence

This section provides a summary of the available scientific research for Taxim - O (Cefixime), focusing only on the structure of the studies and the types of measurements researchers took. This overview is based on authoritative scientific literature and research reports and aims to describe what has been observed so far, without offering clinical advice or making claims about personal outcomes.

Evidence Base for Acute Ear and Throat Infections (Otitis Media and Pharyngitis)

Research was studied for acute episodes like Acute Otitis Media (AOM) and Pharyngitis, primarily in children (6 months and older). Researchers utilized randomized and comparative trial designs. Studies monitored outcomes related to physical discomfort and systemic imbalance, including microbiological outcomes that focus on the presence of targeted bacteria. Findings describe patterns observed when results were tracked against those documented for established treatments.

Evidence Base for Uncomplicated Urinary Tract Infections (UTIs)

This area of research was examined using randomized and prospective trials to evaluate Cefixime in both adult and pediatric populations with uncomplicated urinary tract infections. Studies focused on exploring short-term symptom changes. Outcomes monitored included clinical resolution and the clearance of specific susceptible bacterial strains. Long-term effects are not fully established, as limited follow-up durations mean there is limited information regarding recurrence rates over extended periods.

Evidence Consistency Under Surveillance: Focus on Gonorrhea

The evidence base for uncomplicated urogenital gonorrhea involves historical randomized controlled trials and ongoing surveillance reports. Historical research described high measurements of microbiological clearance for urogenital sites. However, studies monitored lower measurements of clearance at pharyngeal infection sites. Ongoing public health surveillance documents rising minimum inhibitory concentrations (MICs), which indicates decreased bacterial susceptibility over time. Due to this shifting pattern, certainty remains low regarding the current application of monotherapy.

Key Studies & References

  1. Systematic review and meta-analysis on efficacy of cefixime for treating gonococcal infections

Frequently Asked Questions (FAQ)

Common questions about Taxim - O (FAQ)


Q: What kind of infections is Taxim - O typically used to treat?

Regulatory documents list Taxim-O for the treatment of susceptible infections throughout the body. This includes infections in the urinary tract, upper respiratory tract (such as sinusitis, tonsillitis, pharyngitis, and otitis media), and lower respiratory tract (such as bronchitis and pneumonia).


Q: Does Taxim - O work for viral illnesses like the common cold or flu?

No. Taxim-O, as a medicine classified as an antibiotic, is designed to kill or prevent the growth of bacteria. Official statements confirm that this medicine will not work for infections caused by viruses, such as the common cold or the flu.


Q: How quickly can a person expect to feel better after starting Taxim - O?

Official patient information notes that some improvement may be observed during the first few days of treatment. Continued administration of the full course is still necessary. The importance of completing the full course remains.


Q: What is the purpose of completing the entire course of Taxim - O?

Completing the full course of medicine, as defined in official instructions, is intended to help ensure the body is clear of susceptible bacteria. Stopping too soon or skipping doses can allow the infection to persist and may contribute to the surviving bacteria developing resistance to antibiotics.


Q: What is the meaning of the term 'antibiotic resistance' in relation to Taxim - O?

Antibiotic resistance is described by public health bodies as the point when germs (like bacteria) develop the ability to defeat the drugs designed to kill them. This means the bacteria are not killed and can continue to grow, making infections difficult to treat.


Q: Is Taxim - O a single-dose treatment for any specific infection?

The official regimen for the treatment of uncomplicated gonorrhea is a specific single oral dose. Single-dose use has also been examined in studies for the treatment of acute uncomplicated cystitis.


Q: Has any research been published on the overall effectiveness rate of Taxim - O?

While a single overall effectiveness rate is not universally supplied, published studies have described measurements of microbiological clearance for specific infections, such as gonorrhea and uncomplicated urinary tract infections, with results in line with expected outcomes documented in some research.


Q: What types of research evidence support the use of Taxim - O for respiratory infections?

Research evidence has been collected that focuses on outcomes against pathogens commonly causing Upper Respiratory Tract Infections (like otitis media, tonsillitis, pharyngitis, and bronchitis) and Lower Respiratory Tract Infections (like pneumonia).


Q: Why might a doctor prescribe a long course of Taxim - O (e.g., more than seven days)?

Official documentation states that the course duration is determined by the specific infection. It notes that a longer period may be continued for up to 14 days and is sometimes necessary to ensure the complete elimination of specific organisms, such as Streptococcus pyogenes.


Q: Is Taxim - O considered a 'strong' or 'high-power' antibiotic?

Official documentation describes Cefixime as an oral third-generation cephalosporin. This class is noted in regulatory documents for its in vitro bactericidal activity (meaning it kills bacteria in the lab) against a wide variety of bacterial organisms.


Q: What is the difference between Taxim - O and other similar antibiotics like Amoxicillin?

Taxim-O (Cefixime) is officially classified as a Third-generation Cephalosporin. This is different from antibiotics like Amoxicillin, which belongs to the penicillin class. Cephalosporins and penicillins are chemically distinct classes of antimicrobials.


Q: Is it necessary to take Taxim - O at a fixed time of day?

Consistent drug level maintenance is supported by taking the medicine at around the same times every day. Although the drug can be taken without regard to food, consistent daily timing may be recommended.


Q: What happens if a dose of Taxim - O is accidentally missed?

Official patient information describes that a missed dose may be taken as soon as it is remembered. However, if it is close to the time for the next dose, the instruction provided in official sources is to skip the missed dose and not take a double dose.


Q: Is the chewable form of Taxim - O handled differently than the capsule or tablet?

Yes, according to regulatory-derived patient information. The regulatory-derived patient information requires that chewable tablets be completely chewed before swallowing, unlike whole capsules or standard tablets.


Q: Why are some people advised to take Taxim - O with food?

Official data shows that taking the drug with food does not significantly affect overall drug absorption. However, official notes indicate that taking it with food may be associated with reduced gastrointestinal side effects for some patients.


Q: What is the general recommended storage condition for Taxim - O tablets or suspension?

The dry powder for suspension and tablets must be stored at or below a specified maximum temperature and protected from light and moisture. Once reconstituted, the liquid suspension is viable for 14 days and must not be frozen.


Q: Are there any known interactions between Taxim - O and alcohol consumption?

The official prescribing information does not consistently list or warn about a direct interaction between Cefixime and alcohol consumption.


Q: Is Taxim - O safe to use during pregnancy, according to official data?

Official regulatory text states that there are no adequate and well-controlled studies in pregnant women. The drug is classified as being for use only if clearly needed. This determination is made based on professional medical evaluation.


Q: Can Taxim - O reduce the effectiveness of birth control or hormonal contraceptives?

Warnings, often associated with the use of the drug Ethinyl Estradiol (a component in some birth control pills), mention that certain antibiotics like Cefixime may reduce the effects of hormonal contraceptives in some individuals.


Q: Can Taxim - O be taken with antacids or iron supplements?

Drug interaction information notes that both Iron Supplements and Antacids can decrease the overall absorption of Cefixime into the body, which may affect the drug's activity.


Q: Is it true that Taxim - O can cause dark or clay-colored stools?

Official listings of adverse effects include common issues like diarrhea and rare reports of Jaundice (a liver disorder) and hyperbilirubinemia. These conditions are sometimes associated with changes in stool color.


Q: Can using Taxim - O lead to yeast infections in women?

The official adverse reaction listings include reports of candidiasis and vaginitis. Antibiotics can potentially change the body’s normal bacterial flora, which can sometimes lead to an overgrowth of yeast.


Q: Is there a risk of developing seizures while taking Taxim - O?

Official adverse reaction listings for Cefixime include reports of seizures under the Central Nervous System effects. These events, however, are reported in official adverse reaction listings as rare.


Q: Does Taxim - O affect a person's ability to drive or operate machinery?

The adverse event sections note the potential for side effects such as headache and dizziness. This means that if a person experiences side effects such as dizziness or headache, caution may be necessary when performing skilled tasks.


Q: What are the rare but serious skin reactions associated with Taxim - O?

Official documents classify Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as rare but serious adverse reactions.


Q: Does taking Taxim - O cause any changes to the color of urine or eyes (jaundice)?

The official adverse reaction profile includes reports of Jaundice and elevated hyperbilirubinemia (a chemical change in the blood). These conditions may cause the skin or the whites of the eyes to appear yellow.


Q: What if the infection symptoms seem to worsen or return while taking Taxim - O?

Patient-facing information advises that if symptoms do not improve or get worse within the first few days of treatment, a healthcare professional be contacted.


Q: Can Taxim - O be used to treat infections in infants or very young children?

Official regulatory documents consistently state that the safety and effectiveness have not been established in infants younger than six months of age. Use is approved for pediatric patients six months of age and older.

How should Taxim - O be stored and disposed of?

How to Store and Dispose of Taxim - O?

Regulatory documentation defines strict storage and disposal requirements for Taxim-O (Cefixime) to maintain its quality and stability. The dry powder for oral suspension and capsules must be stored at or below a maximum temperature (e.g., 30 C) and protected from both light and moisture.

For the liquid suspension, stability is limited: once reconstituted, the product is viable for 14 days. During this period, it must be kept in a tightly closed container and shaken well before use. The label mandates that the reconstituted suspension must not be frozen.

Official Stability and Disposal Rules

Condition Requirement
In-Use Stability Discard any unused liquid portion after 14 days.
Prohibited Environment Do not freeze the reconstituted suspension.
Safety Rule Keep the medicine out of the sight and reach of children and pets.

Disposal instructions require that any unused or expired medication, especially the liquid, be properly discarded after the stability period, adhering to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Taxim - O found in:

A-Z Index: